Rhenium-186 NanoLiposomes (186RNL) for Recurrent Glioma
This study is looking at the safety and how well a second dose of Rhenium-186 NanoLiposomes (186RNL) works for people with glioma (a type of brain tumor) who have already received one treatment with 186RNL. The 186RNL is given directly into the tumor using a special catheter (a thin tube). Researchers want to see if this second treatment is safe and tolerable, and they will also measure how long people live after treatment. You may be able to join if you are at least 18 years old, have a confirmed glioma diagnosis after your first 186RNL treatment, and can understand and sign the consent forms. This study plans to enroll about 40 participants, but its current recruitment status is unclear.
- Study design
- This is an open-label study, meaning both you and your doctors will know what treatment you are receiving. It is a Phase 1 study, focusing on safety, and plans to enroll about 40 participants.
- What's involved
- You will have a catheter placed in your tumor, and then receive a single dose of 186RNL. You will have follow-up evaluations on days 3, 7, 14, 28, and every 28 days after that until your disease progresses or any side effects are resolved.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for at least 12 weeks to assess side effects, and overall survival will be measured at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Andrew J Brenner, PhD · PRINCIPAL_INVESTIGATOR · The Cancer Therapy and Research Center at UTHSCSA
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Assessment of safety and tolerability of a second dose of 186RNL by CED as part of standard of care >30 days following first dose.> 30 days
Safety and tolerability assessed by number of participants with treatment-related toxicities and/or adverse events as assessed by CTCAE v4.0 with 4-week evaluation periods for toxicity and disease assessment until disease progression is suspected.
- Overall Survival6 Months
To assess overall survival following 186RNL in patients with bevacizumab naïve recurrent glioblastoma following treatment with a second administration of 186RNL.